BHVN - Biohaven Ltd.

QQQ $ 416.48 $ -6.71 (-1.59 %)

DIA $ 378.79 $ 0.31 (0.08 %)

SPY $ 496.37 $ -3.23 (-0.65 %)

TLT $ 89.08 $ -0.28 (-0.31 %)

GLD $ 221.85 $ 1.80 (0.82 %)

Previous Close

$ 42.16

Open

$ 42.88

Bid

$ 0.00 x 0

Ask

$ 39.46 x 400

Day's Range

$ 38.74 - $ 43.18

52 Week Range

$ 12.35 - $ 62.21

Volume

3,668,414

Average Volume

Market Cap

2.87B

Beta (5Y Monthly)

$ 1.78

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-29-2024	12-31-2023	10-K
2	11-14-2023	09-30-2023	10-Q
3	07-31-2023	06-30-2023	10-Q
4	05-12-2023	03-31-2023	10-Q
5	03-23-2023	12-31-2022	10-K
6	11-09-2022	09-30-2022	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Cantor Fitzgerald Reiterates Overweight on...
04/18/2024 13:51:23

Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.

Biohaven Reports Pricing Of Public Offerin...
04/18/2024 10:02:11

The gross proceeds from the offering are expected to be approximately $230 million before deducting underwriting discounts and ...

Biohaven Announces $200M Public Offering O...
04/17/2024 20:15:35

Biohaven Ltd. (NYSE:BHVN), a biopharmaceutical company focused on the discovery, development and commercialization of life-chan...

why-ultragenyx-pharmaceutical-shares-are-trading-lower-by-around-9-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Ultragenyx Pharmaceutical Shares Are T...
04/15/2024 18:11:35

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...

Reported Saturday, Biohaven Showcased Inno...
04/15/2024 06:18:30

Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300...

Cantor Fitzgerald Reiterates Overweight on...
04/10/2024 17:28:02

Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.

RBC Capital Reiterates Outperform on Bioha...
04/09/2024 13:17:16

RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $61 price target.

why-is-obesity-drug-developer-altimmune-stock-trading-lower-on-wednesday

Why Is Obesity Drug Developer Altimmune St...
03/27/2024 13:31:39

Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipos...

obesity-drug-landscape-has-a-contender-from-biohaven-ceo-highlights-different-approach-amid-stiff-competition-from-novo-nordisk-eli-lilly

Obesity Drug Landscape Has A Contender Fro...
03/26/2024 17:48:38

Biohaven's approach to combat obesity. Learn about their experimental drug taldefgrobep alfa (t-alpha), targeting muscle gr...

HC Wainwright & Co. Maintains Buy on Bioha...
03/04/2024 11:35:04

HC Wainwright & Co. analyst Douglas Tsao maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $50 ...

RBC Capital Maintains Outperform on Biohav...
03/01/2024 14:56:40

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and lowers the price target from $62 to...

TD Cowen Maintains Outperform on Biohaven,...
03/01/2024 13:39:04

TD Cowen analyst Tyler Van Buren maintains Biohaven (NYSE:BHVN) with a Outperform and raises the price target from $35 to $55.

Biohaven Q4 EPS $(1.61) Down From $(1.27) YoY
02/29/2024 21:28:24

Biohaven (NYSE:BHVN) reported quarterly losses of $(1.61) per share. This is a 26.77 percent decrease over losses of $(1.27) pe...

this-analyst-is-bullish-on-biohavens-approach-in-neuro-psych-space

This Analyst Is Bullish On Biohaven's Appr...
02/16/2024 18:58:46

Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion acro...

RBC Capital Initiates Coverage On Biohaven...
02/16/2024 11:56:06

RBC Capital analyst Leonid Timashev initiates coverage on Biohaven (NYSE:BHVN) with a Outperform rating and announces Price ...

UBS Initiates Coverage On Biohaven with Bu...
02/06/2024 12:47:05

UBS analyst Ashwani Verma initiates coverage on Biohaven (NYSE:BHVN) with a Buy rating and announces Price Target of $59.

HC Wainwright & Co. Initiates Coverage On ...
12/22/2023 11:12:44

HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Biohaven (NYSE:BHVN) with a Buy rating and announces Pric...

fedex-posts-downbeat-earnings-joins-steelcase-argenx-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session

FedEx Posts Downbeat Earnings, Joins Steel...
12/20/2023 10:33:14

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday.

Baird Initiates Coverage On Biohaven with ...
12/08/2023 10:52:16

Baird analyst Brian Skorney initiates coverage on Biohaven (NYSE:BHVN) with a Outperform rating and announces Price Target o...

JP Morgan Maintains Overweight on Biohaven...
11/20/2023 16:08:52

JP Morgan analyst Tessa Romero maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $26 to $32.

CLASS ACTION DEADLINES - JOIN NOW!

04/22/2024 Dick's Sporting Goods, Inc. (DKS)

04/22/2024 Innodata Inc. (INOD)

04/22/2024 Fox Factory Holding Corp. (FOXF)

04/23/2024 Lantronix, Inc. (LTRX)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)

BHVNBiohaven Ltd.

NYSE biohavenpharma.com

$ 39.32 $ -3.56 (-8.3 %)

Friday, 19-Apr-2024 12:45:57 EDT